AYTU BioPharma AYTU

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.01 (-0.78%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of AYTU BioPharma (AYTU)
    Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1.25

    • Market Cap

      $7.71 Million

    • Price-Earnings Ratio

      -1.29

    • Total Outstanding Shares

      6.17 Million Shares

    • Total Employees

      102

    • Dividend

      No dividend

    • IPO Date

      February 15, 2008

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      7900 e. union avenue, Denver, CO, 80237

    • Homepage

      https://www.aytubio.com

    Historical Stock Splits

    If you bought 960,000 shares of AYTU before July 1, 2016, you'd have 1 share today.
    Execution DateSplit Amount
    January 6, 20231-for-20 (Reverse Split)
    December 9, 20201-for-10 (Reverse Split)
    August 13, 20181-for-20 (Reverse Split)
    August 29, 20171-for-20 (Reverse Split)
    July 1, 20161-for-12 (Reverse Split)

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Financing Activities$-251,000
    Net Cash Flow, Continuing$869,000
    Net Cash Flow From Financing Activities, Continuing$-251,000
    Net Cash Flow From Investing Activities$447,000
    Net Cash Flow From Operating Activities$673,000
    Net Cash Flow From Investing Activities, Continuing$447,000

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Income Tax Expense/Benefit$1.06 Million
    Income/Loss From Continuing Operations After Tax$2.14 Million
    Preferred Stock Dividends And Other Adjustments$0
    Other Operating Expenses$48.88 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Revenues$68.76 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$2.26 Million
    Comprehensive Income/Loss$2.26 Million
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Fixed Assets$516,000
    Current Liabilities$64.05 Million
    Other Current Assets$98.97 Million
    Other Non-current Assets$2.70 Million
    Noncurrent Assets$53.17 Million
    Inventory$11.09 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AYTU from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.